@inbook{1cb17cdc73534eb6ac8f0e748d06bda2,
title = "Drugs in Tuberculosis and Leprosy",
abstract = "The treatment of tuberculosis and leprosy requires the utilization of combination regimens commonly including agents with variable toxicity profiles that may be further exacerbated by drug–drug interactions and patient-specific factors. The increase in incorporation of older and novel agents to treatment regimens has revealed unique adverse effect profiles and added to the previous understanding of these drug's adverse effect profiles. In this chapter we review the pertinent literature from 2017 regarding adverse effects for the following agents: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, delamanid, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thioacetazone.",
keywords = "Adverse effects, Ethambutol, Isoniazid, Leprosy, Pyrazinamide, Rifamycins, Side effect, Tuberculosis",
author = "Ramanathan, {Meenakshi R.} and Howell, {Crystal K.} and Sanders, {James M.}",
note = "Publisher Copyright: {\textcopyright} 2018 Elsevier B.V.",
year = "2018",
month = jan,
day = "1",
doi = "10.1016/bs.seda.2018.06.014",
language = "English (US)",
isbn = "9780444641199",
series = "Side Effects of Drugs Annual",
publisher = "Elsevier B.V.",
pages = "363--376",
editor = "Ray, {Sidhartha D.}",
booktitle = "Side Effects of Drugs Annual",
}